Last 12 months
Inside the activity.
0 purchase rows · 240 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 200 |
| Dec 2025 | 0 | 3 |
| Jan 2026 | 0 | 31 |
| Feb 2026 | 0 | 0 |
| Mar 2026 | 0 | 0 |
| Apr 2026 | 0 | 0 |
| May 2026 | 0 | 2 |
| Jun 2026 | 0 | 1 |
| Jul 2026 | 0 | 0 |
| Aug 2026 | 0 | 3 |
| Sep 2026 | 0 | 0 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 11, 2020 Filed Feb 13, 2020 23:11 UTC |
Shah Aarti S.SVP & CIO
|
GrantRestricted Stock Unit · Derivative | 6,282 | $0.00 | $0.00 |
DisclosureSEC source: 0000059478-20-000042 · wf-form4_158163548313358.xml · derivative · entry 3 Shah Aarti S. · CIK 0001725292 · SVP & CIO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,282 Underlying: Common Stock · 6,282 shares Expires 2021-02-01 F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Eli Lilly and Company common stock. Read SEC document |
| February 11, 2020 Filed Feb 13, 2020 23:11 UTC |
Shah Aarti S.SVP & CIO
|
GrantCommon Stock | 3,767 | $144.25 | $543,389.75 |
DisclosureSEC source: 0000059478-20-000042 · wf-form4_158163548313358.xml · nonDerivative · entry 1 Shah Aarti S. · CIK 0001725292 · SVP & CIO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,087 Read SEC document |
| February 11, 2020 Filed Feb 13, 2020 23:13 UTC |
Skovronsky DanielSVP, CSO, and Pres. LRL
|
GrantCommon Stock | 21,341 | $144.25 | $3,078,439.25 |
DisclosureSEC source: 0000059478-20-000044 · wf-form4_158163562070805.xml · nonDerivative · entry 1 Skovronsky Daniel · CIK 0001741474 · SVP, CSO, and Pres. LRL 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 97,159 Read SEC document |
| February 11, 2020 Filed Feb 13, 2020 23:17 UTC |
Smiley Joshua LSVP and CFO
|
GrantRestricted Stock Unit · Derivative | 19,266 | $0.00 | $0.00 |
DisclosureSEC source: 0000059478-20-000046 · wf-form4_158163583321508.xml · derivative · entry 3 Smiley Joshua L · CIK 0001725189 · SVP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,266 Underlying: Common Stock · 19,266 shares Expires 2021-02-01 F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Eli Lilly and Company common stock. Read SEC document |
| February 11, 2020 Filed Feb 13, 2020 23:17 UTC |
Smiley Joshua LSVP and CFO
|
GrantCommon Stock | 5,447 | $144.25 | $785,729.75 |
DisclosureSEC source: 0000059478-20-000046 · wf-form4_158163583321508.xml · nonDerivative · entry 1 Smiley Joshua L · CIK 0001725189 · SVP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,971 Read SEC document |
| February 11, 2020 Filed Feb 13, 2020 23:19 UTC |
White Anne E.SVP & Pres-Lilly Oncology
|
GrantCommon Stock | 7,079 | $144.25 | $1,021,145.75 |
DisclosureSEC source: 0000059478-20-000048 · wf-form4_158163596956610.xml · nonDerivative · entry 1 White Anne E. · CIK 0001752313 · SVP & Pres-Lilly Oncology 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,122 Read SEC document |
| February 11, 2020 Filed Feb 13, 2020 23:23 UTC |
Zakrowski Donald AChief Accounting Officer
|
GrantCommon Stock | 3,845 | $144.25 | $554,641.25 |
DisclosureSEC source: 0000059478-20-000050 · wf-form4_158163617674766.xml · nonDerivative · entry 1 Zakrowski Donald A · CIK 0001561539 · Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,440 Read SEC document |
| February 11, 2020 Filed Feb 13, 2020 23:25 UTC |
Zulueta Alfonso GSVP & President, Lilly Int'l
|
GrantRestricted Stock Unit · Derivative | 16,754 | $0.00 | $0.00 |
DisclosureSEC source: 0000059478-20-000052 · wf-form4_158163631047243.xml · derivative · entry 3 Zulueta Alfonso G · CIK 0001596336 · SVP & President, Lilly Int'l 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,754 Underlying: Common Stock · 16,754 shares Expires 2021-02-01 F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Eli Lilly and Company common stock. Read SEC document |
| February 11, 2020 Filed Feb 13, 2020 23:25 UTC |
Zulueta Alfonso GSVP & President, Lilly Int'l
|
GrantCommon Stock | 18,322 | $0.00 | $0.00 |
DisclosureSEC source: 0000059478-20-000052 · wf-form4_158163631047243.xml · nonDerivative · entry 1 Zulueta Alfonso G · CIK 0001596336 · SVP & President, Lilly Int'l 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 56,646 Read SEC document |
| February 05, 2020 Filed Feb 6, 2020 19:27 UTC |
LILLY ENDOWMENT INC10% owner
|
SaleCommon Stock | 69,047 | $147.10 | $10,156,744.65 |
DisclosureSEC source: 0001209191-20-007128 · doc4.xml · nonDerivative · entry 2 LILLY ENDOWMENT INC · CIK 0000316011 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 113,520,304 F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $146.905 to $147.34, inclusive. Read SEC document |
| February 05, 2020 Filed Feb 6, 2020 19:27 UTC |
LILLY ENDOWMENT INC10% owner
|
SaleCommon Stock | 130,953 | $146.35 | $19,165,063.22 |
DisclosureSEC source: 0001209191-20-007128 · doc4.xml · nonDerivative · entry 1 LILLY ENDOWMENT INC · CIK 0000316011 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 113,589,351 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $145.90 to $146.85, inclusive. The reporting person undertakes to provide to Eli Lilly & Company, any security holder of Eli Lilly & Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (1) and (2) to this Form 4. Read SEC document |
| February 01, 2020 Filed Feb 4, 2020 20:44 UTC |
Barnes Melissa SChief Eth/Cmpl Ofcr & SVP, ERM
|
Exercise / conversionRestricted Stock Unit · Derivative | 4,896 | $0.00 | $0.00 |
DisclosureSEC source: 0000059478-20-000016 · wf-form4_158084903354660.xml · derivative · entry 4 Barnes Melissa S · CIK 0001566364 · Chief Eth/Cmpl Ofcr & SVP, ERM 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 4,896 shares Expires 2020-02-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Eli Lilly and Company common stock. Read SEC document |
| February 01, 2020 Filed Feb 4, 2020 20:44 UTC |
Barnes Melissa SChief Eth/Cmpl Ofcr & SVP, ERM
|
Tax withholdingCommon Stock | 2,174 | $139.64 | $303,577.36 |
DisclosureSEC source: 0000059478-20-000016 · wf-form4_158084903354660.xml · nonDerivative · entry 2 Barnes Melissa S · CIK 0001566364 · Chief Eth/Cmpl Ofcr & SVP, ERM 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,992 Read SEC document |
| February 01, 2020 Filed Feb 4, 2020 20:44 UTC |
Barnes Melissa SChief Eth/Cmpl Ofcr & SVP, ERM
|
Exercise / conversionCommon Stock | 4,896 | $0.00 | $0.00 |
DisclosureSEC source: 0000059478-20-000016 · wf-form4_158084903354660.xml · nonDerivative · entry 1 Barnes Melissa S · CIK 0001566364 · Chief Eth/Cmpl Ofcr & SVP, ERM 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,166 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 01, 2020 Filed Feb 4, 2020 20:47 UTC |
Fry Stephen FSVP, HR & Diversity
|
Exercise / conversionRestricted Stock Unit · Derivative | 13,055 | $0.00 | $0.00 |
DisclosureSEC source: 0000059478-20-000018 · wf-form4_158084925506456.xml · derivative · entry 4 Fry Stephen F · CIK 0001513324 · SVP, HR & Diversity 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 13,055 shares Expires 2020-02-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Eli Lilly and Company common stock. Read SEC document |
| February 01, 2020 Filed Feb 4, 2020 20:47 UTC |
Fry Stephen FSVP, HR & Diversity
|
Tax withholdingCommon Stock | 5,851 | $139.64 | $817,033.64 |
DisclosureSEC source: 0000059478-20-000018 · wf-form4_158084925506456.xml · nonDerivative · entry 2 Fry Stephen F · CIK 0001513324 · SVP, HR & Diversity 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 107,415 Read SEC document |
| February 01, 2020 Filed Feb 4, 2020 20:47 UTC |
Fry Stephen FSVP, HR & Diversity
|
Exercise / conversionCommon Stock | 13,055 | $0.00 | $0.00 |
DisclosureSEC source: 0000059478-20-000018 · wf-form4_158084925506456.xml · nonDerivative · entry 1 Fry Stephen F · CIK 0001513324 · SVP, HR & Diversity 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 113,266 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 01, 2020 Filed Feb 4, 2020 20:54 UTC |
Ricks David ADirector · President & CEO
|
Exercise / conversionRestricted Stock Unit · Derivative | 69,350 | $0.00 | $0.00 |
DisclosureSEC source: 0000059478-20-000020 · wf-form4_158084966166007.xml · derivative · entry 5 Ricks David A · CIK 0001538604 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 69,350 shares Expires 2020-02-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Eli Lilly and Company common stock. Read SEC document |
| February 01, 2020 Filed Feb 4, 2020 20:54 UTC |
Ricks David ADirector · President & CEO
|
Tax withholdingCommon Stock | 31,089 | $139.64 | $4,341,267.96 |
DisclosureSEC source: 0000059478-20-000020 · wf-form4_158084966166007.xml · nonDerivative · entry 2 Ricks David A · CIK 0001538604 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 195,666 Read SEC document |
| February 01, 2020 Filed Feb 4, 2020 20:54 UTC |
Ricks David ADirector · President & CEO
|
Exercise / conversionCommon Stock | 69,350 | $0.00 | $0.00 |
DisclosureSEC source: 0000059478-20-000020 · wf-form4_158084966166007.xml · nonDerivative · entry 1 Ricks David A · CIK 0001538604 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 226,755 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 01, 2020 Filed Feb 4, 2020 20:59 UTC |
Zulueta Alfonso GSVP & President, Lilly Int'l
|
Exercise / conversionRestricted Stock Unit · Derivative | 16,317 | $0.00 | $0.00 |
DisclosureSEC source: 0000059478-20-000022 · wf-form4_158084994011889.xml · derivative · entry 4 Zulueta Alfonso G · CIK 0001596336 · SVP & President, Lilly Int'l 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 16,317 shares Expires 2020-02-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Eli Lilly and Company common stock. Read SEC document |
| February 01, 2020 Filed Feb 4, 2020 20:59 UTC |
Zulueta Alfonso GSVP & President, Lilly Int'l
|
Tax withholdingCommon Stock | 7,299 | $139.64 | $1,019,232.36 |
DisclosureSEC source: 0000059478-20-000022 · wf-form4_158084994011889.xml · nonDerivative · entry 2 Zulueta Alfonso G · CIK 0001596336 · SVP & President, Lilly Int'l 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,324 Read SEC document |
| February 01, 2020 Filed Feb 4, 2020 20:59 UTC |
Zulueta Alfonso GSVP & President, Lilly Int'l
|
Exercise / conversionCommon Stock | 16,317 | $0.00 | $0.00 |
DisclosureSEC source: 0000059478-20-000022 · wf-form4_158084994011889.xml · nonDerivative · entry 1 Zulueta Alfonso G · CIK 0001596336 · SVP & President, Lilly Int'l 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,623 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 31, 2020 Filed Feb 4, 2020 20:54 UTC |
Ricks David ADirector · President & CEO
|
GiftCommon Stock | 5,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000059478-20-000020 · wf-form4_158084966166007.xml · nonDerivative · entry 3 Ricks David A · CIK 0001538604 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 190,666 Read SEC document |
| January 21, 2020 Filed Jan 23, 2020 22:55 UTC |
TAI JACKSON PDirector
|
GrantCommon Stock | 14 | $140.91 | $1,972.74 |
DisclosureSEC source: 0000059478-20-000008 · wf-form4_157982011591896.xml · nonDerivative · entry 1 TAI JACKSON P · CIK 0001173275 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 58,081 Read SEC document |
| January 13, 2020 Filed Jan 14, 2020 18:37 UTC |
LILLY ENDOWMENT INC10% owner
|
SaleCommon Stock | 21,245 | $139.62 | $2,966,226.90 |
DisclosureSEC source: 0001209191-20-003268 · doc4.xml · nonDerivative · entry 2 LILLY ENDOWMENT INC · CIK 0000316011 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 113,720,304 F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $139.33 to $139.97, inclusive. Read SEC document |
| January 13, 2020 Filed Jan 14, 2020 18:37 UTC |
LILLY ENDOWMENT INC10% owner
|
SaleCommon Stock | 183,755 | $138.84 | $25,512,268.57 |
DisclosureSEC source: 0001209191-20-003268 · doc4.xml · nonDerivative · entry 1 LILLY ENDOWMENT INC · CIK 0000316011 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 113,741,549 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $138.33 to $139.32, inclusive. The reporting person undertakes to provide to Eli Lilly & Company, any security holder of Eli Lilly & Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (1) and (2) to this Form 4. Read SEC document |
| January 10, 2020 Filed Jan 13, 2020 16:00 UTC |
LILLY ENDOWMENT INC10% owner
|
SaleCommon Stock | 210,000 | $138.00 | $28,979,013.00 |
DisclosureSEC source: 0001209191-20-003164 · doc4.xml · nonDerivative · entry 1 LILLY ENDOWMENT INC · CIK 0000316011 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 113,925,304 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $137.70 to $138.27, inclusive. The reporting person undertakes to provide to Eli Lilly & Company, any security holder of Eli Lilly & Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (1) to this Form 4. Read SEC document |
| January 09, 2020 Filed Jan 10, 2020 18:45 UTC |
LILLY ENDOWMENT INC10% owner
|
SaleCommon Stock | 920 | $136.32 | $125,417.16 |
DisclosureSEC source: 0001209191-20-002979 · doc4.xml · nonDerivative · entry 2 LILLY ENDOWMENT INC · CIK 0000316011 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 114,135,304 F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $136.31 to $136.36, inclusive. Read SEC document |
| January 09, 2020 Filed Jan 10, 2020 18:45 UTC |
LILLY ENDOWMENT INC10% owner
|
SaleCommon Stock | 219,080 | $135.79 | $29,749,311.36 |
DisclosureSEC source: 0001209191-20-002979 · doc4.xml · nonDerivative · entry 1 LILLY ENDOWMENT INC · CIK 0000316011 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 114,136,224 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $135.31 to $136.3021, inclusive. The reporting person undertakes to provide to Eli Lilly & Company, any security holder of Eli Lilly & Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (1) and (2) to this Form 4. Read SEC document |
| January 08, 2020 Filed Jan 9, 2020 19:04 UTC |
LILLY ENDOWMENT INC10% owner
|
SaleCommon Stock | 30,434 | $134.04 | $4,079,342.93 |
DisclosureSEC source: 0001209191-20-002675 · doc4.xml · nonDerivative · entry 2 LILLY ENDOWMENT INC · CIK 0000316011 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 114,355,304 F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $133.90 to $134.205, inclusive. Read SEC document |
| January 08, 2020 Filed Jan 9, 2020 19:04 UTC |
LILLY ENDOWMENT INC10% owner
|
SaleCommon Stock | 142,216 | $133.17 | $18,938,762.50 |
DisclosureSEC source: 0001209191-20-002675 · doc4.xml · nonDerivative · entry 1 LILLY ENDOWMENT INC · CIK 0000316011 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 114,385,738 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $132.90 to $133.89, inclusive. The reporting person undertakes to provide to Eli Lilly & Company, any security holder of Eli Lilly & Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (1) and (2) to this Form 4. Read SEC document |
| January 07, 2020 Filed Jan 8, 2020 16:33 UTC |
LILLY ENDOWMENT INC10% owner
|
SaleCommon Stock | 32,645 | $132.90 | $4,338,579.26 |
DisclosureSEC source: 0001209191-20-002450 · doc4.xml · nonDerivative · entry 1 LILLY ENDOWMENT INC · CIK 0000316011 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 114,527,954 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $132.90 to $132.925, inclusive. The reporting person undertakes to provide to Eli Lilly & Company, any security holder of Eli Lilly & Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (1) to this Form 4. Read SEC document |
| January 02, 2020 Filed Jan 6, 2020 22:01 UTC |
Harrington Michael JSenior VP and General Counsel
|
GrantRestricted Stock Unit · Derivative | 1,608 | $0.00 | $0.00 |
DisclosureSEC source: 0000059478-20-000002 · wf-form4_157834805509678.xml · derivative · entry 4 Harrington Michael J · CIK 0001566340 · Senior VP and General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,608 Underlying: Common Stock · 1,608 shares Expires 2021-01-02 F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Eli Lilly and Company common stock. Read SEC document |
| December 20, 2019 Filed Dec 23, 2019 14:48 UTC |
LILLY ENDOWMENT INC10% owner
|
SaleCommon Stock | 19,705 | $132.90 | $2,618,812.23 |
DisclosureSEC source: 0001209191-19-061674 · doc4.xml · nonDerivative · entry 1 LILLY ENDOWMENT INC · CIK 0000316011 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 114,560,599 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $132.90 to $132.93, inclusive. The reporting person undertakes to provide to Eli Lilly & Company, any security holder of Eli Lilly & Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (1) to this Form 4. Read SEC document |
| December 18, 2019 Filed Dec 19, 2019 19:36 UTC |
LILLY ENDOWMENT INC10% owner
|
SaleCommon Stock | 163,014 | $129.45 | $21,101,999.29 |
DisclosureSEC source: 0001209191-19-061259 · doc4.xml · nonDerivative · entry 2 LILLY ENDOWMENT INC · CIK 0000316011 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 114,580,304 F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $129.17 to $129.96, inclusive. Read SEC document |
| December 18, 2019 Filed Dec 19, 2019 19:36 UTC |
LILLY ENDOWMENT INC10% owner
|
SaleCommon Stock | 56,986 | $128.84 | $7,341,848.30 |
DisclosureSEC source: 0001209191-19-061259 · doc4.xml · nonDerivative · entry 1 LILLY ENDOWMENT INC · CIK 0000316011 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 114,743,318 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $128.16 to $129.15, inclusive. The reporting person undertakes to provide to Eli Lilly & Company, any security holder of Eli Lilly & Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (1) and (2) to this Form 4. Read SEC document |
| December 17, 2019 Filed Dec 18, 2019 16:31 UTC |
LILLY ENDOWMENT INC10% owner
|
SaleCommon Stock | 34,182 | $126.60 | $4,327,577.93 |
DisclosureSEC source: 0001209191-19-061070 · doc4.xml · nonDerivative · entry 3 LILLY ENDOWMENT INC · CIK 0000316011 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 114,800,304 F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $126.27 to $126.99, inclusive. Read SEC document |
| December 17, 2019 Filed Dec 18, 2019 16:31 UTC |
LILLY ENDOWMENT INC10% owner
|
SaleCommon Stock | 110,527 | $125.81 | $13,905,733.45 |
DisclosureSEC source: 0001209191-19-061070 · doc4.xml · nonDerivative · entry 2 LILLY ENDOWMENT INC · CIK 0000316011 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 114,834,486 F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $125.27 to $126.26, inclusive. Read SEC document |
| December 17, 2019 Filed Dec 18, 2019 16:31 UTC |
LILLY ENDOWMENT INC10% owner
|
SaleCommon Stock | 70,291 | $125.06 | $8,790,241.01 |
DisclosureSEC source: 0001209191-19-061070 · doc4.xml · nonDerivative · entry 1 LILLY ENDOWMENT INC · CIK 0000316011 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 114,945,013 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $124.27 to $125.26, inclusive. The reporting person undertakes to provide to Eli Lilly & Company, any security holder of Eli Lilly & Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (1), (2), and (3) to this Form 4. Read SEC document |
| December 16, 2019 Filed Dec 18, 2019 19:48 UTC |
Alvarez RalphDirector
|
GrantCommon Stock | 89 | $122.85 | $10,933.65 |
DisclosureSEC source: 0000059478-19-000324 · wf-form4_157669847131436.xml · nonDerivative · entry 1 Alvarez Ralph · CIK 0001310215 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,909 Read SEC document |
| December 16, 2019 Filed Dec 18, 2019 19:51 UTC |
LUCIANO JUAN RDirector
|
GrantCommon Stock | 111 | $122.85 | $13,636.35 |
DisclosureSEC source: 0000059478-19-000326 · wf-form4_157669865882058.xml · nonDerivative · entry 1 LUCIANO JUAN R · CIK 0001455792 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,152 Read SEC document |
| December 16, 2019 Filed Dec 18, 2019 19:53 UTC |
TAI JACKSON PDirector
|
GrantCommon Stock | 17 | $122.85 | $2,088.45 |
DisclosureSEC source: 0000059478-19-000328 · wf-form4_157669881952231.xml · nonDerivative · entry 1 TAI JACKSON P · CIK 0001173275 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 58,067 Read SEC document |
| December 16, 2019 Filed Dec 18, 2019 20:02 UTC |
Walker KarenDirector
|
GrantCommon Stock | 81 | $122.85 | $9,950.85 |
DisclosureSEC source: 0000059478-19-000330 · wf-form4_157669932904464.xml · nonDerivative · entry 1 Walker Karen · CIK 0001642519 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,921 Read SEC document |
| December 09, 2019 Filed Dec 10, 2019 16:49 UTC |
LILLY ENDOWMENT INC10% owner
|
SaleCommon Stock | 10,962 | $119.70 | $1,312,151.40 |
DisclosureSEC source: 0001209191-19-059788 · doc4.xml · nonDerivative · entry 1 LILLY ENDOWMENT INC · CIK 0000316011 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 115,015,304 Read SEC document |
| December 06, 2019 Filed Dec 9, 2019 21:37 UTC |
Zulueta Alfonso GSVP & President, Lilly Int'l
|
SaleCommon Stock | 4,500 | $120.00 | $540,000.00 |
DisclosureSEC source: 0000059478-19-000318 · wf-form4_157592745258343.xml · nonDerivative · entry 1 Zulueta Alfonso G · CIK 0001596336 · SVP & President, Lilly Int'l 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,306 F1 · kind: The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on July 31, 2019. Read SEC document |
| December 06, 2019 Filed Dec 9, 2019 14:51 UTC |
LILLY ENDOWMENT INC10% owner
|
SaleCommon Stock | 400 | $120.70 | $48,280.00 |
DisclosureSEC source: 0001209191-19-059548 · doc4.xml · nonDerivative · entry 2 LILLY ENDOWMENT INC · CIK 0000316011 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 115,026,266 Read SEC document |
| December 06, 2019 Filed Dec 9, 2019 14:51 UTC |
LILLY ENDOWMENT INC10% owner
|
SaleCommon Stock | 193,638 | $120.15 | $23,265,218.42 |
DisclosureSEC source: 0001209191-19-059548 · doc4.xml · nonDerivative · entry 1 LILLY ENDOWMENT INC · CIK 0000316011 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 115,026,666 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $119.70 to $120.69, inclusive. The reporting person undertakes to provide to Eli Lilly & Company, any security holder of Eli Lilly & Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (1) to this Form 4. Read SEC document |
| December 06, 2019 Filed Dec 10, 2019 16:56 UTC |
O'Neill MylesSVP & Pres., Mfg. Operations
|
SaleCommon Stock | 25,000 | $120.00 | $3,000,000.00 |
DisclosureSEC source: 0000059478-19-000320 · wf-form4_157599695974979.xml · nonDerivative · entry 1 O'Neill Myles · CIK 0001725140 · SVP & Pres., Mfg. Operations 10b5-1 filing: Not disclosed Ownership: Indirect · by spouse Disclosed balance after: 33,414 F1 · kind: The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting persons spouse on May 16, 2019. F2 · price: This transaction was executed in multiple trades at prices ranging from $120.00 to $120.33. The price reported reflects the weighted average purchase price. The spouse of the reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F3 · balance_after: This share balance includes a rollover distribution on 02/28/19 of 1095 shares from reporting persons spouse's 401(k) account. F4 · ownership.direct: Reporting person disclaims beneficial ownership of these shares. Read SEC document |
| December 04, 2019 Filed Dec 5, 2019 18:31 UTC |
LILLY ENDOWMENT INC10% owner
|
SaleCommon Stock | 210,000 | $118.52 | $24,890,040.00 |
DisclosureSEC source: 0001209191-19-059237 · doc4.xml · nonDerivative · entry 1 LILLY ENDOWMENT INC · CIK 0000316011 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 115,220,304 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $118.25 to $118.79, inclusive. The reporting person undertakes to provide to Eli Lilly & Company, any security holder of Eli Lilly & Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (1) to this Form 4. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.